MX9606550A - Composiciones de polipeptidos de liberacion controlada y metodos para tratar enfermedad inflamatoria del intestino. - Google Patents

Composiciones de polipeptidos de liberacion controlada y metodos para tratar enfermedad inflamatoria del intestino.

Info

Publication number
MX9606550A
MX9606550A MX9606550A MX9606550A MX9606550A MX 9606550 A MX9606550 A MX 9606550A MX 9606550 A MX9606550 A MX 9606550A MX 9606550 A MX9606550 A MX 9606550A MX 9606550 A MX9606550 A MX 9606550A
Authority
MX
Mexico
Prior art keywords
methods
controlled release
inflammatory bowel
bowel disease
treating inflammatory
Prior art date
Application number
MX9606550A
Other languages
English (en)
Other versions
MXPA96006550A (es
Inventor
Wayne R Gombotz
Siuowfong Wee
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of MX9606550A publication Critical patent/MX9606550A/es
Publication of MXPA96006550A publication Critical patent/MXPA96006550A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invasion se refiere a una formulacion farmacéutica de liberacion controlada que tiene una cantidad efectiva de un polipéptido seleccionado del grupo que consiste en: (a) un receptor de factor de necrosis de tumor (TNFR), (b) receptor de interleucina-1 (IL-1R), (c) receptor antagonista de interleucina-1 (IL.1ra); (d) receptor de interleucina 6 y (e) un anticuerpo monoclonal que es inmunorreactivo contra el factor de necrosis de tumor, la interleucina 6 o interleucina 1; estando el polipéptido encapsulado en alginato. La invencion también se refiere a los métodos para tratar enfermedad inflamatoria del intestino administrando la composicion anterior a un paciente que lo necesite.
MXPA/A/1996/006550A 1994-06-24 1996-12-17 Composiciones de polipeptidos de liberacion controlada y metodos para tratar enfermedad inflamatoria del intestino MXPA96006550A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26558794A 1994-06-24 1994-06-24
US265587 1994-06-24
PCT/US1995/007953 WO1996000081A1 (en) 1994-06-24 1995-06-22 Controlled release polypeptide compositions and methods of treating inflammatory bowel disease

Publications (2)

Publication Number Publication Date
MX9606550A true MX9606550A (es) 1997-07-31
MXPA96006550A MXPA96006550A (es) 1997-12-01

Family

ID=

Also Published As

Publication number Publication date
AU698393B2 (en) 1998-10-29
EP0766564A1 (en) 1997-04-09
EP0766564A4 (en) 1998-09-23
CA2192821A1 (en) 1996-01-04
US6036978A (en) 2000-03-14
WO1996000081A1 (en) 1996-01-04
NZ288997A (en) 1999-01-28
JPH10503179A (ja) 1998-03-24
AU2870995A (en) 1996-01-19

Similar Documents

Publication Publication Date Title
Schwertschlag et al. Hematopoietic, immunomodulatory and epithelial effects of interleukin-11
Seckinger et al. Purification and biologic characterization of a specific tumor necrosis factor α inhibitor
Haque et al. Interferon gamma (IFN‐γ) may reverse oral submucous fibrosis
Germann et al. Interleukin‐12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells
Billiau Gamma-interferon: the match that lights the fire?
CN1322897C (zh) Il-18抑制剂的应用
Bessis et al. The type II decoy receptor of IL‐1 inhibits murine collagen‐induced arthritis
DE68925226T2 (de) Monoklonale Antikörper
DE69724451D1 (de) Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
BG108514A (en) METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
Fujioka et al. Preparation of specific antibodies against murine IL-1ra and the establishment of IL-1ra as an endogenous regulator of bacteria-induced fulminant hepatitis in mice
DK0811384T3 (da) Muskelproteinnedbrydningsinhibitor indeholdende IL-6-receptor-antistof
JPH08505365A (ja) 自己免疫疾患および炎症性疾患の治療
JPH09510444A (ja) 自己免疫疾患の治療におけるil−12およびil−12アンタゴニストの使用
US7741276B2 (en) Use of interleukin-18 inhibitors to inhibit tumor metastasis
Hansen et al. High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro
Hansen et al. Influence of interleukin‐6 (IL‐6) autoantibodies on IL‐6 binding to cellular receptors
Campbell et al. Interleukin (IL)-2, IL-4, and tumor necrosis factor-α responses during Entamoeba histolytica liver abscess development in gerbils
Keegan et al. Superinduction of the murine B cell Fc epsilon RII by T helper cell clones. Role of IL-4.
Van Deuren Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its receptor antagonist during serious infections
US20020025316A1 (en) Pharmaceutical composition containing inhibitors of interferon-gamma
MX9606550A (es) Composiciones de polipeptidos de liberacion controlada y metodos para tratar enfermedad inflamatoria del intestino.
Dallman et al. Cytokines and their receptors in transplantation
Nishimoto et al. Myeloma biology and therapy: present status and future developments
CA2229590C (en) Pharmaceutical composition containing inhibitors of interferon- gamma